within Pharmacolibrary.Drugs.ATC.L;

model L01BB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.01933333333333333,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.022,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0033333333333333335,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01BB03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tioguanine (6-thioguanine) is a purine analogue antimetabolite used primarily in the treatment of acute myeloid leukemia and other hematological malignancies. It is not usually a first-line therapy due to high toxicity risks, including hepatotoxicity and myelosuppression. Tioguanine is approved for use in some countries, but its usage has been reduced in favor of other less toxic thiopurines.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with hematologic malignancies administered oral tioguanine.</p><h4>References</h4><ol><li><p>Toksvang, LN, et al., &amp; Schmiegelow, K (2022). Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. <i>Leukemia</i> 36(7) 1749–1758. DOI:<a href=\"https://doi.org/10.1038/s41375-022-01591-4\">10.1038/s41375-022-01591-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35654820/\">https://pubmed.ncbi.nlm.nih.gov/35654820</a></p></li><li><p>Wang, S, et al., &amp; Song, S (2022). Intestinal microbiota-mediated biotransformations alter the pharmacokinetics of the major metabolites of azathioprine in rats after oral administration. <i>Drug metabolism and pharmacokinetics</i> 45 100458–None. DOI:<a href=\"https://doi.org/10.1016/j.dmpk.2022.100458\">10.1016/j.dmpk.2022.100458</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35569194/\">https://pubmed.ncbi.nlm.nih.gov/35569194</a></p></li><li><p>Yarur, AJ, et al., &amp; Melmed, GY (2023). Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab. <i>Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</i> 21(11) 2908–2917.e10. DOI:<a href=\"https://doi.org/10.1016/j.cgh.2022.10.016\">10.1016/j.cgh.2022.10.016</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36280102/\">https://pubmed.ncbi.nlm.nih.gov/36280102</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01BB03;
